Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S14-S22 , 20 December 2007

Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus

References 

  1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  2. Bronwlee M. Pathogenesis of diabetic complications. Nature. 2001;414:813–820
  3. Cerriello A. Postprandial hyperglycemia and diabetes complications: is time to treat?. Diabetes. 2005;54:1–7
  4. Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic and angiogenic perspectives. Microcirculation. 1997;4:211–232
  5. Krotkiewski M, Bjorntrop P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J. Clin. Invest. 1983;72:1150–1162
  6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003;112:1796–1808
  7. Ahima RS, Filer JS. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000;11:327–332
  8. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. 2001;280:E827–E847
  9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipocyte expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91
  10. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subject release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998;83:847–850
  11. Bruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue: inhibitory effect of anti-diabetic compounds, the thiazolidinendione ciglitazone and the biguanide metformin. Horm. Metab. Res. 2000;32:537–541
  12. Skruk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C. The proatherogonic cytokine interleukin-18 is secreted by human adipocytes. Eur. J. Endocrinol. 2005;152:863–868
  13. Zhang Y, Proneca R, Maffei M, Barone M, Leopold L, Fridmann JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432
  14. Steppan CM, Balley ST, Bath S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312
  15. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995;270:26746–26749
  16. Fukahara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430
  17. Christiansen T, Richelsen B, Bruun M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbidly obese subjects. Int. J. Obes. 2005;29:146–150
  18. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein contributes to insulin resistance and obesity in type 2 diabetes mellitus. Nature. 2005;436:356–362
  19. Karlsson C, Lindell K, Ottoson M, Sjostrom L, Carlsson B, Carlsson LMS. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angitensin II. J. Clin. Endocrinol. Metab. 1998;83:3925–3929
  20. Shimomura L. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 1996;2:800–803
  21. Wajchenberg BL. Subcutaneous and visceral adipose tissue; their relation to the metabolic syndrome. Endocr. Rev. 2000;21:697–738
  22. Sharma AM, Staels B. Peroxisome proliferators activated receptors γ (PPARγ) and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 2007;92:386–395
  23. Hammerstad A, Andersson CX, Rotter Sopaskis V, Smith V. The effects of PPARγ ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids. 2005;73:65–75
  24. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003;112:1821–1830
  25. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 2006;6:177–181
  26. Gonzalez-Manchon C, Ayuso MS, Parrilla R. Control of hepatic gluconeogenesis: role of fatty acid oxidation. Arch. Biochem. Biophys. 1989;271:1–9
  27. Kahn BB, Flier JS. Obesity and insulin resistance. J. Clin. Invest. 2000;106:473–481
  28. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 1996;97:2859–2865
  29. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effect of acute changes on plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes. 2001;50:1612–1617
  30. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglicerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51:2005–2011
  31. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, et al. Free fatty acid induced insulin resistance is associated with activation of protein kinase C θ and alterations in insulin signaling cascade. Diabetes. 1999;48:1270–1274
  32. Ikeda Y, Olsen GS, Ziv E, Hansen LL, Busch AK, Hansen BF, et al. Cellular mechanism of nutritionally induced insulin resistance in Psammomys obesus. Overexpression of protein kinase Cɛ in skeletal muscle precedes the onset of hyperinsulinemia and hyperglycemia. Diabetes. 2001;50:584–592
  33. Oliver MF. Prevention of ventricular fibrillation during acute myocardial ischemia: control of free fatty acids. J. Cardiovasc. Pharmacol. Ther. 2001;6:213–217
  34. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52:2882–2887
  35. Pilz S, Scharnagl H, Tiran B, Seelhorst U, Wellnitz B, Bohem BO, et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrinol. Metab. 2006;91:2542–2547
  36. Considine RV, Sinha MK, Heiman MC, Kraminnas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentration in normal-weight and obese humans. N. Engl. J. Med. 1996;334:292–295
  37. Kowalska I, Strączkowski M, Kinalska I. Levels of leptin in plasma of patients with type 2 diabetes. Pol. Arch. Med. Wewn. 1998;99:470–476
  38. Farooqi IS, Jeeb SA, Langmack G, Lawrence E, Cheetham CC, Prentice AM, et al. Effect of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999;341:879–884
  39. Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract. Res. Clin. Endocrinol. Metab. 2002;16:653–666
  40. Considine RV. Human leptin: an adipocyte hormone with weight-regulatory and endocrine function. Semin. Vasc. Med. 2005;5:15–24
  41. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189:47–60
  42. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Ballacicco M, Rizzon P, et al. Plasma leptin is independently associated with the intima media-thickness of the common carotid artery. Int. J. Obes. 2001;25:805–810
  43. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J. Am. Coll. Cardiol. 2004;44:1819–1829
  44. Reilly MP, Igbal N, Schutta M, Wolfe ML, Scally M, Localio AR, et al. Plasma leptin levels are associated with coronary aterosclerosis in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004;89:3782–3788
  45. Le Lay S, Boucher J, Rey A, Castan-Laurell I, Krief S, Ferre P, et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem. Biophys. Res. Commun. 2001;289:564–567
  46. Juan CC, Au L, Fnag V, Kang SF, Ko YH, Kuo SF, et al. Suppressed gene expression of adipocyte resistin in an insulin—resistant rat model probably by elevated free fatty acids. Biochem. Biophys. Res. Commun. 2001;289:1328–1333
  47. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 2001;285:561–564
  48. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferators-activated receptor-γ action in humans. Diabetes. 2001;50:2199–2202
  49. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 2002;10:1–5
  50. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR γ activators. Biochem. Biophys. Res. Commun. 2003;300:472–476
  51. Young B, Yu K, Park HJ, Lee NS, Min SS, Youn MY, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2004;89:150–156
  52. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005;48:2330–2333
  53. Fehmann H, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm. Metab. Res. 2002;34:671–673
  54. Bokarewa M, Nagaev I, Dalhberg L, Smith U, Tarkowski A. Resistin an adipokine with potent proinflammatory cytokine properties. J. Immunol. 2005;174:5789–5795
  55. Verma S, Li SH, Wang CH, Fedark PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation. 2003;187:736–740
  56. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis. 2005;182:241–248
  57. Reilly MP, Lehrke M, Wolfe ML, Rohatagi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–939
  58. Chandran M, Philips AS, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diab. Care. 2003;26:2442–2450
  59. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–769
  60. Matsuzawa Y, Funahashi T, Kitara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2004;24:29–33
  61. Hotta K, Funahshi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50:1126–1133
  62. Hotta K, Funahshi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000;20:1595–1599
  63. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population (Letter). Lancet. 2002;360:57–58
  64. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999;257:79–83
  65. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N Osaka CAD Study Group-Coronary Artery Disease. Association of hipoadiponectinemia with coronary artery disese in men. Arterioscler. Thromb. Vasc. Biol. 2003;23:85–89
  66. Adamczak W, Więcek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentrations in patients with essential hypertension. Am. J. Hypertens. 2003;16:72–75
  67. Kowalska I, Straczkowski M, Nikołajuk A, Krukowska A, Kinalska I, Górska M. Plasma adiponectin concentration and tumor necrosis factor-α system activity in lean non-diabetic offspring of type 2 diabetic subjects. Eur. J. Endocrinol. 2006;154:319–324
  68. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001;7:941–946
  69. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, Goodyear LJ. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes. 2000;49:527–531
  70. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 1999;277:E1–E10
  71. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002;8:1288–1295
  72. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–1888
  73. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737
  74. Kojima S, Funahshi T, Sakamoto T, Miyamato S, Soejima H, Hokamahi J, et al. The variation of plasma concentration of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003;89:667–668
  75. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–2770
  76. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 2004;89:2563–2568
  77. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Hotta K, et al. Adiponectin, an adipocyte-derived plasma protein, inhbits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–1301
  78. Kowalska I, Straczkowski M, Nikołajuk A, Kinalska I, Górska M, Prokop J, et al. Plasma adiponectin and E selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv. Med. Sci. 2006;56:94–98
  79. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2 dependent mechanism. Nat. Med. 2005;11:1096–1103
  80. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005;67:705–713
  81. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al. Adiponectin-mediated modulation of hypertrophic signals. Nat. Med. 2004;10:1384–1389
  82. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. TCM. 2006;16:141–146
  83. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996;334:1717–1725
  84. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 1995;95:2409–2415
  85. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFα by human muscle: relationship to insulin resistance. J. Clin. Invest. 1996;97:1111–1116
  86. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity-induced insulin resistance. Science. 1996;271:665–668
  87. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNFα function. Nature. 1997;389:610–614
  88. Mingrone G, Rosa G, Di Rocco P, Manco M, Capristo E, Castagneto M, et al. Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-alpha reduction and GLUT4 expression enhancement. Int. J. Obes. 2002;26:1165–1172
  89. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 2004;47:1029–1037
  90. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46:451–455
  91. Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757–1762
  92. Straczkowski M, Kowalska I, Stepien A, Dzienis-Straczkowska S, Szelachowska M, Kinalska I. Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diab. Care. 2002;25:1824–1828
  93. Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, Stepien A, Kowalska I, Kinalska I. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diab. Care. 2003;26:875–880
  94. Straczkowski M, Kowalska I, Dzienis-Straczkowska S, Stepien A, Skibinska E, Szelachowska M, et al. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur. J. Endocrinol. 2001;145:273–280
  95. Lattuada G, Sereni LP, Ruggieri D, Scollo A, Benedini S, Ragogna F, et al. Postabsorptive and insulin-stimulated energy homeostasis and leucine turnover in offspring of type 2 diabetic patients. Diab. Care. 2004;27:2716–2722
  96. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia. 2003;46:625–633
  97. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNFα antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996;45:881–885
  98. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intavenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 2000;85:1316–1319
  99. Di Rocco P, Manco M, Rosa G, Greco AV, Mingrone G. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes. Res. 2004;12:734–739
  100. Kim F, Gallis B, Corson MA. TNFα inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am. J. Physiol. 2001;280:C1057–C1065
  101. Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNFα. Diabetes. 2000;49:1904–1909
  102. Fernandez-Real JM, Molina A, Broch M, Ricart W, Gutierrez C, Casamitjana R, et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes. 1999;48:1108–1112
  103. Kaartinen M, Penttila A, Kovanen P. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNFα. Circulation. 1996;94:2787–2792
  104. Siwik DA, Chang DLF, Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in vitro. Circ. Res. 2000;86:1259–1265
  105. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S, et al. Expression of PAI-1 in human adipose tissue: a role for TNFα?. Atherosclerosis. 1999;143:81–90
  106. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 1993;132:2246–2253
  107. Fernandez-Real JM, Gutierrez C, Ricart W, Castineira MJ, Vendrell J, Richart C. Plasma levels of the soluble fraction of TNFα receptors 1 and 2 are independent determinants of total and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis. 1999;146:321–327
  108. Couffinhal T, Duplaa C, Labat L, Lamaziere JM, Moreau C, Printzeva O, et al. Tumor necrosis factor-α stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler. Thromb. 1993;13:407–414
  109. Straczkowski M, Lewczuk P, Dzienis-Strączkowska S, Kowalska I, Stepien A, Kinalska I. Elevated soluble intercellular adhesion molecule-1 levels in obesity: relationship to insulin resistance and tumor necrosis factor-alpha system activity. Metabolism. 2002;51:75–78
  110. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J. Clin. Endocrinol. Metab. 2002;87:4602–4606
  111. Lainez B, Fernandez-Real JM, Romero X, Esplugues E, Canete JD, Ricart W, et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int. Immunol. 2004;16:169–177
  112. Fernandez-Real JM, Straczkowski M, Lainez B, Chacon MR, Kowalska I, Lopez-Bermejo A, et al. An alternative spliced variant of circulating soluble tumor necrosis factor-alpha receptor-2 is paradoxically associated with insulin action. Eur. J. Endocrinol. 2006;154:723–730
  113. Fernandez-Real JM, Botas-Cervero P, Lainez B, Ricart W, Delgado E. An alternatively spliced soluble TNFα receptor is associated with metabolic disorders: a replication study. Clin. Immunol. 2006;121:236–241

PII: S0168-8227(07)00518-9

doi: 10.1016/j.diabres.2007.10.007

Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S14-S22 , 20 December 2007

Article Tools